Merck says remigromig meets primary endpoint in pivotal BRUNELLO trial for diabetic macular edema

Merck reported topline results from the pivotal Phase 2b/3 BRUNELLO trial of remigromig in adults with diabetic macular edema. Year-one data will be presented Oct. 10 at the American Academy of Ophthalmology Annual Meeting. Both remigromig doses met the primary goal, matching ranibizumab on vision outcomes over 52 weeks. Safety was generally acceptable, though remigromig showed higher rates of serious eye complications and more discontinuations than ranibizumab. Merck plans regulatory discussions while continuing a second pivotal DME study, positioning remigromig as a potential new mechanism in retinal disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via (Ref. ID: 20260924103567) on September 24, 2026, and is solely responsible for the information contained therein. (C)